Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;11(2):175-178.
doi: 10.1136/neurintsurg-2018-014032. Epub 2018 Jun 5.

Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension

Athos Patsalides  1 , Cristiano Oliveira  2   3 , Jessica Wilcox  2 , Kenroy Brown  1 , Kartikey Grover  4 , Yves Pierre Gobin  1 , Marc J Dinkin  2   3
Affiliations

Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension

Athos Patsalides et al. J Neurointerv Surg. 2019 Feb.

Abstract

Aims: We report the cerebrospinal fluid opening pressure (CSF-OP) measurements obtained before and after venous sinus stenting (VSS) in 50 patients with idiopathic intracranial hypertension.

Methods: The CSF-OP was measured with a spinal tap 3 months before and 3 months after treatment. All data were prospectively collected and included patient demographics, weight (kg), body mass index (BMI), acetazolamide daily dosage (mg), procedural details, complications, venous sinus pressures (mm Hg), trans-stenotic pressure gradient (mm Hg), transverse sinus symmetry, and type of venous sinus stenosis.

Results: The average pretreatment CSF-OP was 37 cm H2O (range 25-77) and the average post-treatment CSF-OP was 20.2 cm H2O (range 10-36), with an average reduction of 16.8 cm H2O (P<0.01). The post-treatment CSF-OP was less than 25 cm H2O in 40/50 patients. The average acetazolamide daily dose decreased from 950 mg to 300 mg at the time of 3-month follow-up (P<0.01). No patient required an increase in acetazolamide dose 3 months after VSS. The average weight before treatment was 95.4 kg with an average BMI of 35.41. There was an average increase in body weight of 1.1 kg at the 3-month follow-up with an average increase in BMI of 0.35 (P=0.03).

Conclusions: We provide evidence that there is a significant decrease in CSF-OP in patients with idiopathic intracranial hypertension 3 months after VSS, independent of acetazolamide usage or weight loss.

Keywords: intracranial pressure; stenosis; stent; vein.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr Gobin is the founder, medical director and CEO of Serenity Medical None declared.

References

    1. Donnet A, Metellus P, Levrier O, et al. . Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients. Neurology 2008;70:641–7. 10.1212/01.wnl.0000299894.30700.d2 - DOI - PubMed
    1. Elder BD, Goodwin CR, Kosztowski TA, et al. . Venous sinus stenting is a valuable treatment for fulminant idiopathic intracranial hypertension. J Clin Neurosci 2015;22:685–9. 10.1016/j.jocn.2014.10.012 - DOI - PubMed
    1. Smith KA, Peterson JC, Arnold PM, et al. . A case series of dural venous sinus stenting in idiopathic intracranial hypertension: association of outcomes with optical coherence tomography. Int J Neurosci 2017;127:145–53. 10.3109/00207454.2016.1152967 - DOI - PubMed
    1. Dinkin MJ, Patsalides A. Venous sinus stenting in idiopathic intracranial hypertension: results of a prospective trial. J Neuroophthalmol 2017;37:113–21. 10.1097/WNO.0000000000000426 - DOI - PubMed
    1. Matloob SA, Toma AK, Thompson SD, et al. . Effect of venous stenting on intracranial pressure in idiopathic intracranial hypertension. Acta Neurochir 2017;159:1429–37. 10.1007/s00701-017-3229-6 - DOI - PubMed